AmSurg-Envision merger closer to final stages as Hart-Scott-Rodino waiting period expires: 5 things to know

Listen

The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired for the Envision Healthcare/AmSurg merger.

Here are five key notes:

1. The waiting period is with respect to the U.S. Federal Trade Commission review of the proposed merger between AmSurg and Envision.

2. Waiting for the expiration period to end satisfies one of the conditions of the merger’s closing.

3. The merger is subject to other closing conditions, including shareholder approval from both Envision and AmSurg. There are additional regulatory approvals to come as well.

4. AmSurg and Envision separately received a request for information from the antitrust division of the State of Florida Attorney General’s office. Both organizations are cooperating with the request.

5. The two companies signed a definitive merger agreement in June 2016 with the combined companies reporting a pro forma market cap of around $10 billion. AmSurg shareholders have 47 percent stake of the company and Envision shareholders have around 53 percent stake.
https://www.beckersasc.com/asc-transactions-and-valuation-issues/amsurg-envision-healthcare-finalize-10b-merger-8-things-to-know.html

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers